Ping An Biomedical Co., Ltd. Announces Receipt of Nasdaq Minimum Bid Price Deficiency Letter

Ping An Biomedical (Nasdaq: PASW) received a Nasdaq Minimum Bid Price Deficiency Letter after its closing bid price failed to meet the $1.00 minimum for the period Oct 10, 2025–Nov 20, 2025.

Rhea-AI Summary

Ping An Biomedical (Nasdaq: PASW) received a Nasdaq Minimum Bid Price Deficiency Letter after its closing bid price failed to meet the $1.00 minimum for the period Oct 10, 2025–Nov 20, 2025. Nasdaq provided an 180-calendar-day compliance period ending May 25, 2026 to regain compliance.

If not cured, the company may be eligible for an additional 180 days only if it meets market value and other initial listing standards (except bid price) and files intent to cure; otherwise Nasdaq may issue a delisting notice. The company is evaluating options, including a possible reverse stock split, but cannot assure successful compliance.

Positive

• Nasdaq granted a 180-day compliance period until May 25, 2026
• Potential additional 180-day cure window if other listing standards met

Negative

• Closing bid price below $1.00 for Oct 10–Nov 20, 2025
• Risk of Nasdaq delisting if deficiency is not cured
• Possible reverse stock split may be required to regain compliance
• No assurance company will regain compliance within the period

Argus Nov 28 session

-3.59% close to close Open Argus

Details

News Market Reaction – PASW

On Nov 28, the day this news came out, PASW closed 3.59% below the previous close.

Data tracked by StockTitan Argus for the Nov 28 session.

Market Context

This announcement detailed Nasdaq’s notice that PASW failed to meet the $1.00 minimum bid price requ...

Analysis

This announcement detailed Nasdaq’s notice that PASW failed to meet the $1.00 minimum bid price requirement, triggering an initial 180-day compliance period ending May 25, 2026, with potential for an additional 180 days if other standards are satisfied. The company indicated it might consider tools such as a reverse stock split. Investors should monitor any formal plans to cure the deficiency and future disclosures on Nasdaq listing status.

Key Figures

Nasdaq minimum bid: $1.00 per share Initial compliance period: 180 calendar days Additional compliance period: 180 calendar days +5 more

Nasdaq minimum bid

$1.00 per share

Minimum bid price under Nasdaq Listing Rules 5550(a)(2)

Initial compliance period

180 calendar days

First Nasdaq compliance window ending May 25, 2026

Additional compliance period

180 calendar days

Potential second window if other listing standards are met

Current share price

$0.5785

Price before news; below Nasdaq $1.00 bid requirement

52-week high

$1.22

Pre-news 52-week high for PASW

52-week low

$0.3447

Pre-news 52-week low for PASW

Today’s volume

91,240 shares

Compared with 20-day average volume of 413,931 shares

Market capitalization

$11,010,550

Pre-news market cap for PASW

Historical Context

1 past event · Latest: Nov 28

1 event

1. Nov 28

   Nasdaq compliance notice

   24h Move

   -3.6%

   Nasdaq minimum bid price deficiency letter and risk of potential delisting.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

Nasdaq Listing Rules 5550(a)(2), reverse stock split, forward-looking statements, prospectus, +1 more

5 terms

Nasdaq Listing Rules 5550(a)(2) regulatory

"no longer meets the continued listing requirement of Nasdaq under Nasdaq Listing Rules 5550(a)(2)"

Nasdaq Listing Rule 5550(a)(2) is a Nasdaq Capital Market standard that sets a minimum share-price requirement companies must meet to list their common stock on that market. Think of it as a minimum entrance score for a club: if a stock trades below the required price, the company can face warnings or removal, which matters to investors because it affects liquidity, tradability and perceptions of company stability.

reverse stock split financial

"its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary"

A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.

forward-looking statements regulatory

"FORWARD-LOOKING STATEMENTS Certain statements in this announcement are forward-looking statements"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

prospectus regulatory

"encourages investors to read the risk factors contained in the Company’s final prospectus and other reports"

A prospectus is a detailed document that explains a company's plans for offering new shares or investments to the public. It’s important because it provides potential investors with key information about the company’s business, risks, and how they might make money, helping them decide whether to invest. Think of it as a guidebook for understanding what you're buying into.

Nasdaq Capital Market regulatory

"all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement"

The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Hong Kong, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Ping An Biomedical Co., Ltd. (Nasdaq: PASW) (the “Company”) today announced receipt of Nasdaq Minimum Bid Price Deficiency Letter.

On November 24, 2025, Ping An Biomedical Co., Ltd. (the “Company”) received a letter from the Listing Qualifications staff of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that based on the closing bid price of the Company for the period from October 10, 2025 to November 20, 2025, the Company no longer meets the continued listing requirement of Nasdaq under Nasdaq Listing Rules 5550(a)(2), to maintain a minimum bid price of $1 per share.

Nasdaq has provided the Company with an 180 calendar days compliance period, or until May 25, 2026, in which to regain compliance with Nasdaq continued listing requirement. In the event that the Company does not regain compliance in the compliance period, the Company may be eligible for an additional 180 calendar days, should the Company meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and is able to provide written notice of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. However, if it appears that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, Nasdaq will provide notice that the Company’s securities will be subject to delisting.

The Company is currently evaluating options to regain compliance and intends to timely regain compliance with Nasdaq’s continued listing requirement. Although the Company will use all reasonable efforts to achieve compliance with Rule 5550(a)(2), there can be no assurance that the Company will be able to regain compliance with that rule or will otherwise be in compliance with other Nasdaq continued listing requirement. 

ABOUT PING AN BIOMEDICAL CO., LTD.

Ping An Biomedical Co., Ltd. is a one-stop SCM service provider in the apparel industry. It is also a forward-thinking company dedicated to delivering innovative solutions in healthcare and biomedical technology.  

FORWARD-LOOKING STATEMENTS

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations, including the trading of its Ordinary Shares or the closing of the Offering. Investors can find many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct. The Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to read the risk factors contained in the Company’s final prospectus and other reports it files with the SEC before making any investment decisions regarding the Company’s securities. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law.

Contacts

Ping An Biomedical Co., Ltd. Investor Relations Contact:

Building 13, No. 1 Headquarters, No. 5 Kechuang 2nd Street, Tongzhou District, Beijing
Tel : +8618910841158
Email: liupijun2025@163.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Ping An Biomedical (PASW) receive from Nasdaq on Nov 24, 2025?

A Nasdaq Minimum Bid Price Deficiency Letter notifying noncompliance with the $1.00 minimum bid requirement for Oct 10–Nov 20, 2025.

How long does PASW have to regain Nasdaq compliance?

Nasdaq granted an initial 180-calendar-day compliance period, until May 25, 2026.

Can PASW get more time to cure the Nasdaq deficiency?

Yes, an additional 180 days may be available if PASW meets market value and other initial listing standards (except bid price) and files intent to cure.

What actions might PASW take to regain Nasdaq compliance?

The company is evaluating options and may effect a reverse stock split if necessary to raise the bid price.

What happens if PASW does not regain compliance by May 25, 2026?

If unable to cure or ineligible for an extension, Nasdaq may issue a delisting notice for the company’s securities.